Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF120

VEGF120

Brief Information

Name:Vascular endothelial growth factor A
Target Synonym:Vascular Endothelial Growth Factor,VEGF-A,MVCD1,Vascular endothelial growth factor A,VEGF,VEGFA,VPF,Vascular Endothelial Growth Factor A165,Vascular permeability factor,Vascular Endothelial Growth Factor A121
Number of Launched Drugs:25
Number of Drugs in Clinical Trials:68
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
VE0-M82Q2 Mouse Biotinylated Mouse VEGF120 Protein, His,Avitag™
VE0-M82Q2-structure
VE0-M82Q2-sds
VE0-M4211 Mouse ActiveMax® Mouse VEGF120 Protein, Tag Free
VE0-M4211-structure
VE0-M4211-sds

Part of Bioactivity data

VE0-M4211-ELISA
ActiveMax® Mouse VEGF120, Tag FreeActiveMax® Mouse VEGF120, Tag Free (Cat. No. VE0-M4211) ELISA bioactivity

Immobilized ActiveMax® Mouse VEGF120, Tag Free (Cat. No. VE0-M4211) at 2 μg/mL (100 μL/well) can bind Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) with a linear range of 8-31 ng/mL (QC tested).

VE0-M82Q2-ELISA
Biotinylated Mouse VEGF120, His,AvitagBiotinylated Mouse VEGF120, His,Avitag (Cat. No. VE0-M82Q2) ELISA bioactivity

Immobilized VEGFR1/R2 at 2 μg/mL (100 μL/well) can bind Biotinylated Mouse VEGF120, His,Avitag (Cat. No. VE0-M82Q2) with a linear range of 0.1-2 ng/mL (QC tested).

Synonym Name

RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

Background

Vascular endothelial growth factor A (VEGFA) is also known as Vascular permeability factor (VPF). VEGFA belongs to the PDGF/VEGF growth factor family. VEGFA is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. VEGFA is produced by a group of three major isoforms as a result of alternative splicing and if any three isoforms are produced (VEGFA120, VEGFA164, and VEGFA188) then this will not result in vessel defects and death of the full VEGFA knockout in mice.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Bevacizumab biosimilar (Hetero Drugs) Approved Hetero Drugs Cizumab India Colorectal Neoplasms Hetero Drugs 2016-01-01 Colorectal Neoplasms Details
Ziv-aflibercept BAY-865321; AVE-0005 Approved Regeneron Pharmaceuticals Inc, Sanofi Zaltrap Japan Colorectal Neoplasms Sanofi 2012-08-03 Ovarian Neoplasms; Solid tumours; Ascites; Lung Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Lymphoma; Neoplasm Metastasis Details
Bevacizumab biosimilar (Boan Biopharma) LY-01008 Approved Shandong Boan Biotechnology Co Ltd 博优诺 Mainland China Carcinoma, Hepatocellular Shandong Boan Biotechnology Co Ltd 2021-05-07 Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Bevacizumab biosimilar (Zydus Cadila) Approved Zydus Cadila Bryxta India Carcinoma, Non-Small-Cell Lung Zydus Cadila 2017-01-01 Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Dr. Reddy's Laboratories) Approved Dr. Reddy’S Laboratories Ltd Versavo India Glioma; Carcinoma, Renal Cell; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms Dr. Reddy’S Laboratories Ltd 2019-01-01 Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Glioma; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Ranibizumab biosimilar (Intas Biopharmaceuticals) Approved Intas Biopharmaceuticals Razumab India Macular Degeneration Intas Biopharmaceuticals 2015-01-01 Macular Degeneration Details
Bevacizumab Biosimilar (AXXO) Approved Axxo Russian Federation Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms Axxo 2013-01-01 Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Elea) Approved Elea Lumiere Argentina Macular Degeneration Elea 2018-09-01 Macular Degeneration Details
Neovasculgen PI-VEGF165 Approved Human Stem Cells Institute Neovasculgen Russian Federation Peripheral Arterial Disease Human Stem Cells Institute 2011-12-07 Peripheral Arterial Disease Details
Bevacizumab biosimilar (Biocad) BCD-021 Approved Biocad Avegra Russian Federation Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Biocad 2015-11-25 Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Conbercept FP-3; KH-902 Approved Chengdu Kanghong Biotechnologies Co Ltd 朗沐, Langmu Mainland China Macular Degeneration Chengdu Kanghong Biotechnologies Co Ltd 2013-11-27 Macular Edema; Vision Disorders; Wet Macular Degeneration; Diabetic macular oedema; Retinoblastoma; Corneal Neovascularization; Macular Degeneration; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetes Mellitus Details
Bevacizumab biosimilar (Intas Pharmaceuticals) Approved Intas Biopharmaceuticals Bevatas Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Biocon/Mylan) MYL-1402O Approved Biocon KRABEVA EU Carcinoma, Renal Cell; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms Mylan Ire Healthcare Ltd 2017-01-01 Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Brain Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Ranibizumab biosimilar (Samsung Bioepis) SB-11 Approved Samsung Bioepis BYOOVIZ United States Macular Degeneration; Macular Edema; Choroidal Neovascularization null, Samsung Bioepis Co Ltd 2021-08-18 Macular Edema; Wet Macular Degeneration; Macular Degeneration; Choroidal Neovascularization; Diabetic Retinopathy Details
Bevacizumab biosimilar (Innovent Biologics) IBI-305; IBI305; IBI 305 Approved Innovent Biologics(Suzhou) Co Ltd 达攸同, BYVASDA Mainland China Carcinoma, Hepatocellular Innovent Biologics(Suzhou) Co Ltd 2020-06-17 Glioblastoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Jiangsu Hengrui Medicine) BP-102 Approved Jiangsu Hengrui Medicine Co Ltd Mainland China Rectal Neoplasms; Carcinoma, Non-Small-Cell Lung Suzhou Suncadia Biopharmaceuticals Co Ltd 2021-06-22 Solid tumours; Rectal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab biosimilar (Betta/Mabworks) MIL-60 Approved Institute Of Basic Medicine, Chinese Academy Of Medical Sciences, Beijing Mabworks Biotech Co Ltd 贝安汀 Mainland China Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms Betta Pharmaceuticals Co Ltd 2021-11-24 Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
Bevacizumab biosimilar (TOT Biopharm) TAB-008; TOT-102; TAB008; TOT102 Approved Tot Biopharm Co Ltd 朴欣汀, Pusintin Mainland China Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms Tot Biopharm Co Ltd 2021-12-01 Glioblastoma; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Aflibercept BAT-86-5321; BAY-865321 Approved Regeneron Pharmaceuticals Inc, Bayer Ag Eylea Mainland China Macular Degeneration; Macular Edema Bayer Australia Ltd 2011-11-18 Diabetes Complications; Neoplasm Metastasis; Retinopathy of Prematurity; Retinal Vein Occlusion; Macular Degeneration; Diabetic Retinopathy; Diabetes Mellitus; Retinal Degeneration; Colorectal Neoplasms; Diabetes Mellitus, Type 1; Prostatic Neoplasms; Wet Macular Degeneration; Diabetic macular oedema; Myopia, Degenerative; Retinal Diseases; Glaucoma, Neovascular; Diabetes Mellitus, Type 2; Macular Edema Details
Bevacizumab biosimilar (Shanghai Henlius Biotech) HLX-04; HLX04-O Approved Shanghai Henlius Biotech Co Ltd Mainland China Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Shanghai Henlius Biopharmaceuticals Co Ltd 2021-11-30 Solid tumours; Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Macular Degeneration Details
Ranibizumab biosimilar (Senju) GBS-007; OT-701; SJP-0133 Approved Senju Pharmaceutical Co Ltd Japan Macular Degeneration Senju Pharmaceutical Co Ltd 2021-09-27 Macular Degeneration Details
Bevacizumab biosimilar (Bio-Thera Solutions) BAT-1706 Approved Bio-Thera Solutions Ltd 普贝希 Mainland China Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Beigene Ltd, Bio-Thera Solutions Ltd 2021-11-17 Ovarian Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular Details
Ranibizumab rhuFab-V2; Y-0317; RFB-002; RG-6321; RG-3645; rhu-Fab-VEG; AMD-rhuFab-V2; AMD-Fab Approved Novartis Pharma Ag, Genentech Inc Lucentis, 诺适得, Susvimo Japan Diabetic macular oedema Novartis Pharma Ag 2006-06-30 Macular Edema; Vision Disorders; Glaucoma, Neovascular; Neovascularization, Pathologic; Myopia, Degenerative; Retinal Diseases; Diabetic macular oedema; Wet Macular Degeneration; Retinal Degeneration; Macular Degeneration; Choroidal Neovascularization; Diabetic Retinopathy; Retinal Vein Occlusion; Diabetes Mellitus; Myopia; Retinopathy of Prematurity Details
Faricimab RG-7716; RO-6867461 Approved F. Hoffmann-La Roche Ltd, Genentech Inc Vabysmo United States Diabetic macular oedema; Wet Macular Degeneration Genentech Inc 2022-01-28 Macular Edema; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Mellitus; Macular Degeneration; Retinal Vein Occlusion Details
Bevacizumab biosimilar (mAbixience) MB02; BEVZ-92; BEVZ92-MB02 Approved Mabxience Alymsys EU Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Breast Neoplasms; Uterine Cervical Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms Stada Arzneimittel Ag, Mabxience Sa 2013-10-25 Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab biosimilar (Allergan/Amgen) ABP-215 Approved Amgen Inc Mvasi Japan Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell Daiichi Sankyo Co Ltd 2017-09-14 Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab biosimilar (Samsung Bioepis) SB-8; SP-8 Approved Samsung Bioepis Aybintio EU Carcinoma, Ovarian Epithelial; Uterine Cervical Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Carcinoma, Renal Cell Samsung Bioepis Nl Bv 2020-08-19 Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab biosimilar (Pfizer) PF-6439535; PF-06439535 Approved Pfizer Inc Zirabev United States Peritoneal Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms Pfizer Inc 2019-02-14 Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab G180CU; RO-4876646; RG-435; NSC-704865; G180CL; R-435; G180DL Approved Genentech Inc 安维汀, Avastin Mainland China Carcinoma, Hepatocellular Roche Pharmaceutical Co Ltd 2004-02-26 Peritoneal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Macular Degeneration; Carcinoma, Hepatocellular; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Glioma; Fallopian Tube Neoplasms; Ovarian Neoplasms; Colorectal Neoplasms; Brain Neoplasms; Sarcoma; Breast Neoplasms; Multiple Myeloma; Glioblastoma; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Liver Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LHA-510 LHA-510 Phase 2 Clinical Alcon Macular Degeneration Details
Ranibizumab biosimilar (Pfenex) PF-582 Phase 2 Clinical Pfenex Macular Degeneration Details
Ranibizumab biosimilar (Shanghai United Cell Biotechnology) Phase 1 Clinical Shanghai United Cell Biotechnology Co Ltd Macular Edema; Macular Degeneration Details
LMG-324 LMG-324 Phase 2 Clinical Alcon Macular Degeneration Details
Bevacizumab biosimilar (Celltrion) CT-16; CTP-16 Phase 3 Clinical Celltrion Adenocarcinoma of Lung; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (AryoGen Biopharma) Phase 3 Clinical Aryogen Biopharma Colorectal Neoplasms Details
Ranibizumab biosimilar (CJSC Generium) GNR-067 Phase 1 Clinical Cjsc Generium Macular Degeneration Details
Aflibercept biosimilar (Sam Chun Dang Pharm) SCD-411 Phase 3 Clinical Sam Chun Dang Pharm Co Ltd Macular Degeneration Details
Aflibercept Biosimilar (Clover Biopharmaceuticals) SCB-420 Phase 1 Clinical Sichuan Sanyecao Bio-Pharmaceutical Co Ltd Diabetic macular oedema; Macular Degeneration Details
CLS-1002 CLS-1002 Phase 1 Clinical Clearside Biomedical Macular Degeneration Details
Aflibercept biosimilar (Momenta/Mylan) M-710; MYL-1701P Phase 3 Clinical Mylan, Momenta Diabetic macular oedema Details
Bevacizumab biosimilar (Alphamab/R-Pharm) RPH-001 Phase 3 Clinical Suzhou Alphamab Co Ltd, R-Pharm Colorectal Neoplasms Details
Bevacizumab biosimilar (Tanvex BioPharma) TX-16 Phase 1 Clinical Tanvex Biopharma Colorectal Neoplasms Details
Aflibercept biosimilar (CinnaGen)(阿柏西普生物类似药(CinnaGen)) Phase 3 Clinical Cinnagen Macular Degeneration Details
Ranibizumab biosimilar (Lupin) LUBT-010 Phase 3 Clinical Rubin Ltd Macular Degeneration Details
Bevacizumab biosimilar (Eastern Biotech) JY-028 Phase 1 Clinical Beijing Eastern Biotech Co Ltd Wet Macular Degeneration; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (JHL Biotech) JHL-1149 Phase 1 Clinical JHL Biotech Ovarian Neoplasms; Colorectal Neoplasms; Lung Neoplasms Details
Colorectal cancer vaccine (Immunovo/Pepscan Therapeutics) Phase 1 Clinical Pepscan Systems Colorectal Neoplasms Details
Aflibercept Biosimilar (Boan Biopharma/Luye Pharma) LY-09004; BA-9101; OT-702 Phase 3 Clinical Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd Wet Macular Degeneration; Macular Degeneration Details
Bevacizumab biosimilar (Synermore Biologics) SYN-050 Phase 1 Clinical Lonn Ryonn Pharma Ltd Neoplasms Details
Bevacizumab biosimilar (Hualan Biological Engineering) WBP-264 Phase 3 Clinical Hualan Genetic Engineering Co Ltd Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Muparfostat sodium PI-88 Phase 3 Clinical Australian National University Liver Neoplasms; Solid tumours; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Ranibizumab biosimilar (Qilu Pharmaceutical) BCD-300; QL-1205 Phase 3 Clinical Qilu Pharmaceutical Co Ltd, Biocnd Wet Macular Degeneration; Macular Degeneration Details
Ranibizumab biosimilar (Reliance Life Sciences Group) R-TPR-024 Phase 3 Clinical Reliance Life Sciences Macular Degeneration Details
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code) Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms; Colorectal Neoplasms Details
OB-318 OB-318 Phase 1 Clinical Oneness Biotech Solid tumours; Carcinoma, Hepatocellular Details
SCT-501(National Cancer Institute) SCT-501 Phase 2 Clinical National Cancer Institute Kidney Neoplasms Details
Ziv-aflibercept biosimiliar (Boan Biopharma) LY-01012; BA-1103 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Colorectal Neoplasms Details
Bevacizumab biosimilar (Gedeon Richter) Phase 1 Clinical Gedeon Richter Plc Neoplasms Details
CT-P42 CT-P42 Phase 3 Clinical Celltrion Diabetic macular oedema Details
Bevacizumab biosimilar (CTTQ Pharma) TQ-B2302 Phase 3 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Ovarian Neoplasms; Glioblastoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
MP-0250 MP-0250 Phase 2 Clinical Molecular Partners Neoplasms; Multiple Myeloma; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics) HD-204 Phase 3 Clinical Hanwha Biologics Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ranibizumab biosimilar (Xbrane) Phase 3 Clinical Xbrane Biopharma Macular Degeneration Details
ALS-L1023 ALS-L1023 Phase 2 Clinical Angiolab Inc Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Obesity; Macular Degeneration Details
Aflibercept/Nesvacumab REGN 910-3 Phase 2 Clinical Regeneron Pharmaceuticals Inc Diabetic macular oedema; Macular Degeneration Details
AZD-8601 mRNA-AZD-8601; AZD-8601 Phase 2 Clinical Astrazeneca Pharmaceutical Co Ltd Heart Failure Details
Varisacumab R-84; GNR-011; AT-001-IBCG Phase 3 Clinical Peregrine, Ut Southwestern Medical Center Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Reliance Life Sciences) R-TPR-023 Phase 3 Clinical Reliance Life Sciences Colorectal Neoplasms Details
Intravitreal ranibizumab (Sultan Qaboos University) Phase 2 Clinical Sultan Qaboos University Retinal Dysplasia Details
Dilpacimab ABT-165; DVD-Ig ABT-165 Phase 2 Clinical Abbvie Inc Solid tumours; Neoplasms; Colorectal Neoplasms Details
BI-695502 BI-695502 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Brain Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Cipla BioTec) CBT-124 Phase 3 Clinical Cipla Gmbh Carcinoma, Non-Small-Cell Lung Details
FYB-203 FYB-203 Phase 3 Clinical Formycon Macular Degeneration Details
Ranibizumab biosimilar (Chong Kun Dang Pharmaceutical) CKD-701 Phase 3 Clinical Chong Kun Dang Pharmaceutical Corp Macular Degeneration Details
Bevacizumab biosimilar (Oncobiologics) ONS-1045; ONS-5010 Phase 3 Clinical Outlook Therapeutics Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Retinal Vein Occlusion Details
Recombinant anti-VEGF humanized monoclonal antibody (Jiangsu Aosaikang Pharmaceutical) ASK-1202; AMD-B; AK-3008 Phase 3 Clinical Jiangsu Aosaikang Pharmaceutical Co Ltd Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Aflibercept biosimilar (Qilu Pharmaceutical) QL-1207 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Diabetic macular oedema; Macular Degeneration Details
Aflibercept biosimilar (Mabwell) 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 Phase 3 Clinical Mabwell (Shanghai) Bioscience Co Ltd Diabetic macular oedema Details
Aflibercept Biosimilar(Alvotech Swiss) AVT-06 Phase 3 Clinical Alvotech Swiss Ag Macular Degeneration Details
Bevacizumab biosimilar (Centus Biotherapeutics) FKB-238 Phase 3 Clinical Fujifilm Kyowa Kirin Biologics Co Ltd Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Aflibercept biosimilar (Amgen) ABP-938 Phase 2 Clinical Amgen Inc Macular Degeneration Details
Aflibercept biosimilar (Samsung Bioepis) SB-15 Phase 3 Clinical Samsung Bioepis Macular Degeneration Details
Eylea Biosimilar (Alteogen) ALT-L9 Phase 1 Clinical Alteogen Inc, Kissei Pharmaceutical Macular Degeneration Details
TR-009 NOV-1501; ABL001-ABL Bio; ABL-001-ABL Bio; ES-104; CTX-009 Phase 2 Clinical Abl Bio Solid tumours; Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms Details
RC-28 RC28-E; RC-28-E; RC-28 Phase 2 Clinical RemeGen Co Ltd Wet Macular Degeneration; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration Details
ASC-06 ALN-VSP; ALN-VSP01; ALN-VSP02; ASC-06 Phase 1 Clinical Alnylam Pharmaceuticals Inc Solid tumours; Liver Neoplasms Details
Bevacizumab (Beijing Science Sun) K-11; K11 Phase 3 Clinical Beijing Science Sun Pharmaceutical Co Ltd Glioblastoma; Neoplasms; Diabetic macular oedema; Glioma; Carcinoma, Hepatocellular Details
Emvododstat PTC-299 Phase 3 Clinical Ptc Therapeutics Inc Pneumonia; Esophageal Neoplasms; Neurofibromatosis 2; Coronavirus Disease 2019 (COVID-19); Neurofibromatoses; Breast Neoplasms; Coronavirus Infections; Leukemia, Myeloid, Acute; Sarcoma, Kaposi Details
ASKG-712 ASKG712 Phase 1 Clinical Suzhou aosaikang biomedical Co Ltd Wet Macular Degeneration Details
BI-836880 BI-836880 Phase 2 Clinical Ablynx Wet Macular Degeneration; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
Sevacizumab 9MW0211; 9MW-0211; SIM-BD-0801; EPI-0030; BD-0801; TK-001; APX-003 Phase 3 Clinical Epitomics Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Wet Macular Degeneration; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Macular Degeneration Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message